Qi Qiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qi Qiao has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Li Kong
Huazhong University of Science and Technology
4 shared publications- Zhiping Zhang
Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, China
4 shared publications Xiong Liu
Huazhong University of Science and Technology
3 shared publicationsBoning Niu
Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, China
2 shared publicationsConglian Yang
Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, China
2 shared publicationsKexin Cui
Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, China
2 shared publications
Latest Publications
- 2 September 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (36) , 25162-25182
Fluorinated Liposome-Coated Coacervates: Low-Energy Interfaces for Mucus Penetration and Pulmonary Delivery in Acute Respiratory Distress Syndrome
Pulmonary inhalation offers a direct route for drug delivery in acute respiratory distress syndrome (ARDS). However, the efficacy of inhaled therapeutics is often limited by poor stability during nebulization and inability to penetrate the mucus layer. This study developed an inhalation delivery system using fluorinated liposome-coated coacervates (PD-Coac@LipF) for the combined delivery of prednisolone sodium phosphate (PSP) and deoxyribonuclease I (DNase I) to treat ARDS. The coacervate core, formed by liquid–liquid phase separation, could efficiently enrich both PSP and macromolecular DNase I and protect their activity during nebulization. Surface modification with fluorinated liposomes enhanced mucus penetration due to the low surface energy of fluorocarbon chains, enabling rapid diffusion through the pulmonary mucus barrier. Upon deposition in the inflammatory alveolar microenvironment, PD-Coac@LipF adhered to neutrophil extracellular traps (NETs) and facilitated DNase I-mediated degradation, whereas PSP concurrently drived macrophage repolarization toward the anti-inflammatory M2 phenotype. PD-Coac@LipF demonstrated to reduce reactive oxygen species, downregulate pro-inflammatory cytokines, decrease neutrophil infiltration, and alleviate lung injury in ARDS mice. The system also exhibited excellent lung retention and distribution, offering a promising strategy for targeted, efficient, and stable pulmonary inhalation therapy against diseases.
- 2 September 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (36) , 25162-25182
Fluorinated Liposome-Coated Coacervates: Low-Energy Interfaces for Mucus Penetration and Pulmonary Delivery in Acute Respiratory Distress Syndrome
Pulmonary inhalation offers a direct route for drug delivery in acute respiratory distress syndrome (ARDS). However, the efficacy of inhaled therapeutics is often limited by poor stability during nebulization and inability to penetrate the mucus layer. This study developed an inhalation delivery system using fluorinated liposome-coated coacervates (PD-Coac@LipF) for the combined delivery of prednisolone sodium phosphate (PSP) and deoxyribonuclease I (DNase I) to treat ARDS. The coacervate core, formed by liquid–liquid phase separation, could efficiently enrich both PSP and macromolecular DNase I and protect their activity during nebulization. Surface modification with fluorinated liposomes enhanced mucus penetration due to the low surface energy of fluorocarbon chains, enabling rapid diffusion through the pulmonary mucus barrier. Upon deposition in the inflammatory alveolar microenvironment, PD-Coac@LipF adhered to neutrophil extracellular traps (NETs) and facilitated DNase I-mediated degradation, whereas PSP concurrently drived macrophage repolarization toward the anti-inflammatory M2 phenotype. PD-Coac@LipF demonstrated to reduce reactive oxygen species, downregulate pro-inflammatory cytokines, decrease neutrophil infiltration, and alleviate lung injury in ARDS mice. The system also exhibited excellent lung retention and distribution, offering a promising strategy for targeted, efficient, and stable pulmonary inhalation therapy against diseases.
- Open Access
- 4 August 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 171
Comparative efficacy and safety of antibacterial regimens for severe Stenotrophomonas maltophilia infections: A systematic review and network meta-analysis
- 4 August 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 171
Open AccessComparative efficacy and safety of antibacterial regimens for severe Stenotrophomonas maltophilia infections: A systematic review and network meta-analysis
- 3 January 2024
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 18 (2) , 1658-1677
Engineered Biomimetic Nanovesicles Based on Neutrophils for Hierarchical Targeting Therapy of Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome (ARDS) is a clinically severe respiratory disease that causes severe medical and economic burden. To improve therapeutic efficacy, effectively targeting delivery to the inflamed lungs and inflamed cells remains an ongoing challenge. Herein, we designed engineered biomimetic nanovesicles (DHA@ANeu-DDAB) by fusion of lung-targeting functional lipid, neutrophil membrane containing activated β2 integrins, and the therapeutic lipid, docosahexaenoic acid (DHA). By the advantage of lung targeting lipid and β2 integrin targeting adhesion, DHA@ANeu-DDAB can first target lung tissue and further target inflammatory vascular endothelial cells, to achieve "tissue first, cell second" hierarchical delivery. In addition, the β2 integrins in DHA@ANeu-DDAB could bind to the intercellular cell adhesion molecule-1/2 (ICAM-1/2) ligand on the endothelium in the inflamed blood vessels, thus inhibiting neutrophils' infiltration in the blood circulation. DHA administration to inflamed lungs could effectively regulate macrophage phenotype and promote its anti-inflammatory activity via enhanced biosynthesis of specialized pro-resolving mediators. In the lipopolysaccharide-induced ARDS mouse model, DHA@ANeu-DDAB afforded a comprehensive and efficient inhibition of lung inflammation and promoted acute lung damage repair. Through mimicking physiological processes, these engineered biomimetic vesicles as a delivery system possess good potential in targeting therapy for ARDS.
- 3 January 2024
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 18 (2) , 1658-1677
Engineered Biomimetic Nanovesicles Based on Neutrophils for Hierarchical Targeting Therapy of Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome (ARDS) is a clinically severe respiratory disease that causes severe medical and economic burden. To improve therapeutic efficacy, effectively targeting delivery to the inflamed lungs and inflamed cells remains an ongoing challenge. Herein, we designed engineered biomimetic nanovesicles (DHA@ANeu-DDAB) by fusion of lung-targeting functional lipid, neutrophil membrane containing activated β2 integrins, and the therapeutic lipid, docosahexaenoic acid (DHA). By the advantage of lung targeting lipid and β2 integrin targeting adhesion, DHA@ANeu-DDAB can first target lung tissue and further target inflammatory vascular endothelial cells, to achieve "tissue first, cell second" hierarchical delivery. In addition, the β2 integrins in DHA@ANeu-DDAB could bind to the intercellular cell adhesion molecule-1/2 (ICAM-1/2) ligand on the endothelium in the inflamed blood vessels, thus inhibiting neutrophils' infiltration in the blood circulation. DHA administration to inflamed lungs could effectively regulate macrophage phenotype and promote its anti-inflammatory activity via enhanced biosynthesis of specialized pro-resolving mediators. In the lipopolysaccharide-induced ARDS mouse model, DHA@ANeu-DDAB afforded a comprehensive and efficient inhibition of lung inflammation and promoted acute lung damage repair. Through mimicking physiological processes, these engineered biomimetic vesicles as a delivery system possess good potential in targeting therapy for ARDS.
- 29 August 2022
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 16 (9) , 15124-15140
Hybrid Biomimetic Nanovesicles to Drive High Lung Biodistribution and Prevent Cytokine Storm for ARDS Treatment
Acute respiratory distress syndrome (ARDS) has been a life threat for patients in ICUs. Vast efforts have been devoted, while no medication has proved viable, which may be ascribed to inadequate drug delivery to damaged tissues and insufficient control of lung inflammation. Given the anti-inflammatory role of M2-type macrophages, M2 macrophage-derived nanovesicles and lung-targeting liposomes are cofused to fabricate hybrid liposomes-nanovesicles (LNVs). Benefiting from the incorporated lung-homing moiety, LNVs demonstrate high pulmonary accumulation with a lung/liver ratio of 14.9, which is approximately 53.3-fold of free nanovesicles. Thus, M2 macrophage-derived nanovesicles can be delivered to lung tissues for executing immunoregulatory functions. LNVs display phagocytosis by the infiltrated neutrophils and macrophages, exhibiting sustained release of preloaded IKK-2 inhibitor (TPCA-1). The integrated nanosystems demonstrate multidimensional suppression of the overwhelming inflammation, such as decreasing infiltration of inflammatory cells, achieving restraint on cytokine storms and alleviating oxidative stress. Therefore, the improved therapeutic outcome in ARDS mice is obtained. Altogether, the hybrid nanoplatform provides a versatile drug delivery paradigm for integrating biological nanovesicles and therapeutic molecules by cofusion of nanovesicles with liposomes, improving lung biodistribution and accomplishing a boosted anti-inflammatory response for ARDS therapy.
- 29 August 2022
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 16 (9) , 15124-15140
Hybrid Biomimetic Nanovesicles to Drive High Lung Biodistribution and Prevent Cytokine Storm for ARDS Treatment
Acute respiratory distress syndrome (ARDS) has been a life threat for patients in ICUs. Vast efforts have been devoted, while no medication has proved viable, which may be ascribed to inadequate drug delivery to damaged tissues and insufficient control of lung inflammation. Given the anti-inflammatory role of M2-type macrophages, M2 macrophage-derived nanovesicles and lung-targeting liposomes are cofused to fabricate hybrid liposomes-nanovesicles (LNVs). Benefiting from the incorporated lung-homing moiety, LNVs demonstrate high pulmonary accumulation with a lung/liver ratio of 14.9, which is approximately 53.3-fold of free nanovesicles. Thus, M2 macrophage-derived nanovesicles can be delivered to lung tissues for executing immunoregulatory functions. LNVs display phagocytosis by the infiltrated neutrophils and macrophages, exhibiting sustained release of preloaded IKK-2 inhibitor (TPCA-1). The integrated nanosystems demonstrate multidimensional suppression of the overwhelming inflammation, such as decreasing infiltration of inflammatory cells, achieving restraint on cytokine storms and alleviating oxidative stress. Therefore, the improved therapeutic outcome in ARDS mice is obtained. Altogether, the hybrid nanoplatform provides a versatile drug delivery paradigm for integrating biological nanovesicles and therapeutic molecules by cofusion of nanovesicles with liposomes, improving lung biodistribution and accomplishing a boosted anti-inflammatory response for ARDS therapy.
- Top Cited PapersOpen Access
- 1 October 2021
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 11 (10) , 3060-3091
Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design
- 1 October 2021
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 11 (10) , 3060-3091
Top Cited PapersOpen AccessNanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design
- 1 September 2020
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 59 (6) , 515-527
Antifungal resistance-modifying multiplexing action of Momordica charantia protein and phosphorylated derivatives on the basis of growth-dependent gene coregulation in Candida albicans
Fungal growth-dependent gene coregulation is strongly implicated in alteration of gene-encoding target proteases ruling with an antifungal resistance niche and biology of resistant mutants. On the basis of multi-alterative processes in this platform, the resistance-modifying strategy is designed in ketoconazole resistant Candida albicans and evaluated with less selective Momordica charantia protein and allosterically phosphorylated derivatives at the Thr102, Thr24 and Thr255 sites, respectively. We demonstrate absolutely chemo-sensitizing efficacy regarding stepwise-modifying resistance in sensitivity, by a load of only 26.23–40.00 μg/l agents in Sabouraud's dextrose broth. Five successive modifying-steps realize the decreasing of ketoconazole E-test MIC50 from 11.10 to a lower level than 0.10 mg/l. With the ketoconazole resistance-modifying, colony undergoes a high-frequency morphological switch between high ploidy (opaque) and small budding haploid (white). A cellular event in the first modifying-step associates with relatively slow exponential growth (ie, a 4-h delay)-dependent action, mediated by agents adsorption. Moreover, multiple molecular roles are coupled with intracellularly and extracellularly binding to ATP-dependent RNA helicase dbp6; the 0.08–2.45 fold upregulation of TATA-box-binding protein, rRNA-processing protein and translation initiation factor 5A; and the 7.52–55.33% decrease of cytochrome P450 lanosterol 14α-demethylase, glucan 1, 3-β glucosidase, candidapepsin-1 and 1-acylglycerol-3-phosphate O-acyltransferase. Spatial and temporal gene coregulation, in the transcription and translation initiation stages with rRNA-processing, is a new coprocessing platform enabling target protease attenuations for resistance-impairing. An updated resistance-modifying measure of these agents in the low-dose antifungal strategic design may provide opportunities to a virtually safe therapy that is in high dose-dependency. A new platform to modify resistance is fungal growth-dependent gene coregulation. MAP30 and phosphorylated derivatives are candidate resistance-modifying agents. Low-dose stepwise treatment absolutely modifies azole resistance in model fungus.
- 1 September 2020
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 59 (6) , 515-527
Antifungal resistance-modifying multiplexing action of Momordica charantia protein and phosphorylated derivatives on the basis of growth-dependent gene coregulation in Candida albicans
Fungal growth-dependent gene coregulation is strongly implicated in alteration of gene-encoding target proteases ruling with an antifungal resistance niche and biology of resistant mutants. On the basis of multi-alterative processes in this platform, the resistance-modifying strategy is designed in ketoconazole resistant Candida albicans and evaluated with less selective Momordica charantia protein and allosterically phosphorylated derivatives at the Thr102, Thr24 and Thr255 sites, respectively. We demonstrate absolutely chemo-sensitizing efficacy regarding stepwise-modifying resistance in sensitivity, by a load of only 26.23–40.00 μg/l agents in Sabouraud's dextrose broth. Five successive modifying-steps realize the decreasing of ketoconazole E-test MIC50 from 11.10 to a lower level than 0.10 mg/l. With the ketoconazole resistance-modifying, colony undergoes a high-frequency morphological switch between high ploidy (opaque) and small budding haploid (white). A cellular event in the first modifying-step associates with relatively slow exponential growth (ie, a 4-h delay)-dependent action, mediated by agents adsorption. Moreover, multiple molecular roles are coupled with intracellularly and extracellularly binding to ATP-dependent RNA helicase dbp6; the 0.08–2.45 fold upregulation of TATA-box-binding protein, rRNA-processing protein and translation initiation factor 5A; and the 7.52–55.33% decrease of cytochrome P450 lanosterol 14α-demethylase, glucan 1, 3-β glucosidase, candidapepsin-1 and 1-acylglycerol-3-phosphate O-acyltransferase. Spatial and temporal gene coregulation, in the transcription and translation initiation stages with rRNA-processing, is a new coprocessing platform enabling target protease attenuations for resistance-impairing. An updated resistance-modifying measure of these agents in the low-dose antifungal strategic design may provide opportunities to a virtually safe therapy that is in high dose-dependency. A new platform to modify resistance is fungal growth-dependent gene coregulation. MAP30 and phosphorylated derivatives are candidate resistance-modifying agents. Low-dose stepwise treatment absolutely modifies azole resistance in model fungus.
- Open Access
- 26 June 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (28) , 7361-7366
CIDE domains form functionally important higher-order assemblies for DNA fragmentation
Cell death-inducing DFF45-like effector (CIDE) domains, initially identified in apoptotic nucleases, form a family with diverse functions ranging from cell death to lipid homeostasis. Here we show that the CIDE domains of Drosophila and human apoptotic nucleases Drep2, Drep4, and DFF40 all form head-to-tail helical filaments. Opposing positively and negatively charged interfaces mediate the helical structures, and mutations on these surfaces abolish nuclease activation for apoptotic DNA fragmentation. Conserved filamentous structures are observed in CIDE family members involved in lipid homeostasis, and mutations on the charged interfaces compromise lipid droplet fusion, suggesting that CIDE domains represent a scaffold for higher-order assembly in DNA fragmentation and other biological processes such as lipid homeostasis.
- 26 June 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (28) , 7361-7366
Open AccessCIDE domains form functionally important higher-order assemblies for DNA fragmentation
Cell death-inducing DFF45-like effector (CIDE) domains, initially identified in apoptotic nucleases, form a family with diverse functions ranging from cell death to lipid homeostasis. Here we show that the CIDE domains of Drosophila and human apoptotic nucleases Drep2, Drep4, and DFF40 all form head-to-tail helical filaments. Opposing positively and negatively charged interfaces mediate the helical structures, and mutations on these surfaces abolish nuclease activation for apoptotic DNA fragmentation. Conserved filamentous structures are observed in CIDE family members involved in lipid homeostasis, and mutations on the charged interfaces compromise lipid droplet fusion, suggesting that CIDE domains represent a scaffold for higher-order assembly in DNA fragmentation and other biological processes such as lipid homeostasis.